643 related articles for article (PubMed ID: 34732416)
1. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
[TBL] [Abstract][Full Text] [Related]
2. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
4. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
5. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
[TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
12. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
13. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
14. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
15. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
17. Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
Teng F; Meng X; Wang X; Yuan J; Liu S; Mu D; Zhu H; Kong L; Yu J
Oncotarget; 2016 Sep; 7(39):64318-64329. PubMed ID: 27602763
[TBL] [Abstract][Full Text] [Related]
18. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
19. Prognostic value of PD-L1 expression in combination with CD8
Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
